Co-Diagnostics (NASDAQ: CODX) was one of the best-performing stocks of 2020, but a fourth-quarter earnings report failed to impress investment banks that follow the molecular diagnostics company. The stock has been under pressure since Maxim downgraded the stock to hold, and H.C. Wainwright cut its price target on Co-Diagnostics by nearly half.
Is Co-Diagnostics a good stock to buy on the dip, or should you remain cautious?
Image source: Getty Images.
Source Fool.com